About Us
Katya Tsaioun, PhD
Bruno Villoutreix, PhD
Bruno Villoutreix, PhD
20+ years experience in academia and Boston area biotech industry; successful entrepreneur (founded Apredica, an ADME-Tox CRO in 2006, exit to Cyrpotex, PLC (now Evotec)); expertise in mechanistic strategies of de-risking drug-discovery programs.
Bruno Villoutreix, PhD
Bruno Villoutreix, PhD
Bruno Villoutreix, PhD
25+ years at the interface between molecular medicine (cancer, complement system, blood coagulation), structural bioinformatics and chemoinformatics in different countries (USA, Finland, Sweden, Bulgaria, France), both in the private and academic sectors. Research director at INSERM U1141 (the French National Institute of Health and Medic
25+ years at the interface between molecular medicine (cancer, complement system, blood coagulation), structural bioinformatics and chemoinformatics in different countries (USA, Finland, Sweden, Bulgaria, France), both in the private and academic sectors. Research director at INSERM U1141 (the French National Institute of Health and Medical Research), Hospital Robert Debré, Paris, France. Biomolecular modeling, drug design, ADME-Tox prediction
Lana Gladstein, J.D.
Bruno Villoutreix, PhD
Usamah Kayyali, Ph.D.
Chief Legal Officer, Arranta Bio; previously EVP and General Counsel of Brammer Bio (exit to Thermo Fisher in 2019); formerly partner at Troutman Pepper, and partner at Nutter, Boston, MA
Usamah Kayyali, Ph.D.
Usamah Kayyali, Ph.D.
Usamah Kayyali, Ph.D.
Dr. Usamah Kayyali previously conducted research over two decades in molecular and cell biology of disease at Harvard and Tufts, which was funded by the NIH and other agencies. His lab demonstrated a role for p38 MAP kinase-MK2 activation in augmenting the vascular endothelium, and developed an MK2-activating peptide as a potential drug. He currently serves as Scientific Advisor for Akttyva.
Mark Tepper, PhD
Usamah Kayyali, Ph.D.
Mario DiPaola, PhD
Dr. Tepper has over 30 years of experience in the biotechnology and pharmaceutical industry. He has led drug discovery & drug development programs that span a wide range of therapeutic areas including Oncology, Immunology, Rheumatology, Endocrinology, Metabolic Diseases, CNS Diseases, Inflammation and Pain. In addition, he has founded m
Dr. Tepper has over 30 years of experience in the biotechnology and pharmaceutical industry. He has led drug discovery & drug development programs that span a wide range of therapeutic areas including Oncology, Immunology, Rheumatology, Endocrinology, Metabolic Diseases, CNS Diseases, Inflammation and Pain. In addition, he has founded multiple companies based on novel technologies in the area of RNA interference, structure-based drug design, small molecule and protein therapeutics, biosensors, microfluidics and biomaterials. He has taken 2 of his companies public (RXii & CRBP) and sold one in a trade sale to KNSA.
Mario DiPaola, PhD
Usamah Kayyali, Ph.D.
Mario DiPaola, PhD
Dr. Mario DiPaola is an experienced executive with a 25-year record in the biotechnology and pharmaceutical industries. He is the founder or co-founder of a number of companies, including Blue Stream Labs Inc., Oncovolution LLC, Therabene LLC and Higher-Order Technologies LLC. He is also the author of several patents and 50+ publications.